Total submissions: 2
| Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
|---|---|---|---|---|---|---|---|---|
| Women's Health and Genetics/Laboratory Corporation of America, |
RCV003230610 | SCV003929030 | uncertain significance | not specified | 2023-04-24 | criteria provided, single submitter | clinical testing | Variant summary: CYP21A2 c.1132G>T (p.Asp378Tyr) results in a non-conservative amino acid change in the encoded protein sequence. Three of five in-silico tools predict a damaging effect of the variant on protein function. The variant was absent in 235358 control chromosomes (gnomAD). The available data on variant occurrences in the general population are insufficient to allow any conclusion about variant significance. c.1132G>T has been reported in the literature in an individual affected with Congenital Adrenal Hyperplasia (Karlsson_2019), who was reported as compound heterozygous with a pathogenic variant in trans. However this individual also had a variant in cis which showed reduced enzyme activity in vitro. This report does not provide unequivocal conclusions about association of the variant with Congenital Adrenal Hyperplasia. At least one publication reports experimental evidence evaluating an impact on protein function, showing 81% and 58% of normal enzymatic activity towards 17OHP and progesterone, respectively (Karlsson_2019). One submitter has provided a clinical-significance assessments for this variant to ClinVar after 2014, and classified the variant as uncertain significance. Based on the evidence outlined above, the variant was classified as uncertain significance. |
| Institute of Human Genetics, |
RCV000984574 | SCV001132632 | uncertain significance | Classic congenital adrenal hyperplasia due to 21-hydroxylase deficiency | 2019-05-24 | no assertion criteria provided | clinical testing |